Changes in lymphocyte number during cancer chemotherapy and their relation to clinical response

International Journal of Biological Markers

Volumn 14, Issue 2, 1999, Pages 115-117

  Lissoni, Paolo ^a   Fumagalli, L ^a   Paolorossi, F ^a   Mandala M ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

Chemotherapy; Lymphocytes; Non small cell lung cancer

Indexed keywords

CISPLATIN; ETOPOSIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; LYMPHOCYTE COUNT; MALE; STATISTICAL ANALYSIS;

EID: 0032999188     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460089901400209     Document Type: Article

References (10)

1. Maltoni M, Pirovano M, Nanni O, et al. Biological indices predictive of survival in 519 Italian terminally ill cancer patients. J Pain Symptom Management 1997; 13: 1-9.
2. Devereux S, Linch DC. Clinical significance of the haemopoietic growth factors. Br J Cancer 1989; 61: 2-5.
3. Morgan DA, Ruscetti FW, Gallo RG. Selective in vitro growth of T lymphocytes from normal human bone marrow. Science 1976; 193: 1007-8.
4. Whittington R, Faulds D. Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer. Drugs 1993; 46: 446-514.
5. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980; 65: 25-32.
6. Katsumata N, Eguchi K, Fukuda M, et al. Serum levels of cytokines in patients with untreated primary lung cancer. Clin Cancer Res 1996; 2: 553-9.
7. De Vita F, Turitto G, Di Grazia M, Frattolillo A, Catalano G. Analysis of interleukin-2/interleukin-2 receptor system in advanced non-small cell lung cancer. Tumori 1998; 84: 33-8.
8. Lissoni P, Barni S, Tancini G, et al. A randomised study with subcutaneous low-dose interleukin-2 alone vs interleukin-2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br J Cancer 1994; 69: 196-9.
9. Schiller JH, Morgan-Ihrig C, Levitt ML. Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer. Am J Clin Oncol 1995; 18: 47-51.
10. Masotti A, Morandini G, Ortolani R, Fumagalli L. Phase-II randomized study of pre-operative IL-2 administration in operable NSCLC. Lung Cancer 1998; 20: 191-202.